Fenwick & West represented Pharmakon Advisors in the transaction.Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
